BeOne Medicines (NASDAQ:ONC) CEO John Oyler Sells 1,949 Shares

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CEO John Oyler sold 1,949 shares of the company’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $257.24, for a total transaction of $501,360.76. Following the completion of the sale, the chief executive officer directly owned 5,697,649 shares in the company, valued at $1,465,663,228.76. This represents a 0.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

John Oyler also recently made the following trade(s):

• On Monday, June 8th, John Oyler sold 4,940 shares of BeOne Medicines stock. The shares were sold at an average price of $270.56, for a total transaction of $1,336,566.40.

BeOne Medicines Stock Up 1.4%

ONC traded up $3.72 during trading on Monday, hitting $268.20. The company had a trading volume of 351,440 shares, compared to its average volume of 258,341. The company has a market cap of $29.43 billion, a PE ratio of 60.00 and a beta of 0.49. The business has a 50-day moving average of $298.56 and a 200-day moving average of $314.03. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.64 and a quick ratio of 3.27. BeOne Medicines Ltd. – Sponsored ADR has a 1-year low of $239.25 and a 1-year high of $385.22.

BeOne Medicines (NASDAQ:ONC) last posted its quarterly earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share (EPS) for the quarter. The firm had revenue of $1.51 billion for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. As a group, analysts forecast that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. Wall Street Zen upgraded shares of BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Guggenheim lifted their price target on shares of BeOne Medicines from $410.00 to $420.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Jefferies Financial Group lowered shares of BeOne Medicines from a “buy” rating to a “hold” rating and decreased their price target for the company from $420.00 to $290.00 in a report on Monday, March 16th. Royal Bank Of Canada lifted their price target on shares of BeOne Medicines from $425.00 to $436.00 and gave the company an “outperform” rating in a report on Tuesday, June 2nd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BeOne Medicines in a report on Monday, April 20th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $390.00.

Institutional Investors Weigh In On BeOne Medicines

Several institutional investors have recently bought and sold shares of ONC. Mariner LLC lifted its holdings in BeOne Medicines by 3.8% in the 4th quarter. Mariner LLC now owns 883 shares of the company’s stock valued at $269,000 after acquiring an additional 32 shares during the last quarter. Signaturefd LLC raised its holdings in BeOne Medicines by 10.7% during the 4th quarter. Signaturefd LLC now owns 340 shares of the company’s stock worth $103,000 after buying an additional 33 shares during the period. Farther Finance Advisors LLC raised its holdings in BeOne Medicines by 21.8% during the 4th quarter. Farther Finance Advisors LLC now owns 218 shares of the company’s stock worth $66,000 after buying an additional 39 shares during the period. CWM LLC raised its holdings in BeOne Medicines by 32.8% during the 4th quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after buying an additional 39 shares during the period. Finally, Benjamin Edwards Inc. raised its holdings in BeOne Medicines by 8.0% during the 4th quarter. Benjamin Edwards Inc. now owns 690 shares of the company’s stock worth $210,000 after buying an additional 51 shares during the period. Institutional investors and hedge funds own 48.55% of the company’s stock.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.